Morphine Postconditioning Protects against Reperfusion Injury via Inhibiting JNK/p38 MAPK and Mitochondrial Permeability Transition Pores Signaling Pathways

被引:30
|
作者
Chen, Zuolei [1 ]
Zhang, Xuewei [2 ]
Liu, Yingzhi [1 ]
Liu, Zhongkai [3 ]
机构
[1] Qingdao Univ, Affiliated Hosp, Dept Anesthesiol, Qingdao 266071, Peoples R China
[2] Qingdao Univ, Affiliated Hosp, Dept Ultrasound, Qingdao 266071, Peoples R China
[3] Linyi Peoples Hosp, Dept Anesthesiol, 27 Jiefang Rd, Linyi 27600, Shandong, Peoples R China
关键词
Morphine; Postconditioning; Reperfusion Injury; JNK; p38MAPKs; Mitochondrial permeability transition pores; ATTENUATES CARDIOMYOCYTE APOPTOSIS; ISCHEMIA/REPERFUSION INJURY; MYOCARDIAL REPERFUSION; P38; MAPK; IN-VITRO; RATS; CARDIOPROTECTION; JNK; DYSFUNCTION; ACTIVATION;
D O I
10.1159/000445605
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Background: The purpose of this study was to determine whether c-jun NH2 amino-terminal kinases (JNK) and p38 mitogen-activated protein kinases (MAPK) were involved in morphine postconditioning (MpostC). Methods: The isolated rat hearts were randomly assigned into one of the following groups. Hearts in the time control (TC) group were constantly perfused for 105min. Hearts in the ischemia-reperfusion (I/R) group were subjected to 45 min of ischemia followed by 1 h of reperfusion. MpostC was induced by 10 min of morphine administration at the onset of reperfusion. Anisomycin (an activator of JNK/p38 kinases) was administered with or without morphine during the first 10 min of reperfusion following the 45 min of ischemia. Mitochondria and cytosolic proteins were prepared to detect mitochondrial permeability transition (MPT) and cytochrome C (Cyt-c) respectively. Results: MpostC markedly reduced infarct size (IS/AAR), CK-MB release, and improved cardiac function recovery. However, these protective effects were partly abolished in the presence of anisomycin. I/R significantly increased the phosphorylation of JNK and p38 kinases, mitochondrial permeability transition (MPT) opening and Cyt-c release, while these effects were partly abolished by MpostC. The inhibitory effects of MpostC on the phosphorylation of JNK/p38 kinases, MPT opening and Cyt-c release were totally reversed by Anisocycin, which, used individually, did not show any influence on perfusion injury. Conclusions: These findings suggest that MpostC protects isolated rat hearts against reperfusion injury via inhibiting JNK/p38 MAPKs and mitochondrial permeability transition pores signaling pathways. (C) 2016 The Author(s) Published by S. Karger AG, Basel
引用
收藏
页码:61 / 70
页数:10
相关论文
共 50 条
  • [21] Notoginsenoside R1 protects against myocardial ischemia/reperfusion injury in mice via suppressing TAK1-JNK/p38 signaling
    Jing-jing Zeng
    Han-qing Shi
    Fang-fang Ren
    Xiao-shan Zhao
    Qiao-ying Chen
    Dong-juan Wang
    Lian-pin Wu
    Mao-ping Chu
    Teng-fang Lai
    Lei Li
    Acta Pharmacologica Sinica, 2023, 44 : 1366 - 1379
  • [22] Notoginsenoside R1 protects against myocardial ischemia/reperfusion injury in mice via suppressing TAK1-JNK/p38 signaling
    Zeng, Jing-jing
    Shi, Han-qing
    Ren, Fang-fang
    Zhao, Xiao-shan
    Chen, Qiao-ying
    Wang, Dong-juan
    Wu, Lian-pin
    Chu, Mao-ping
    Lai, Teng-fang
    Li, Lei
    ACTA PHARMACOLOGICA SINICA, 2023, 44 (07) : 1366 - 1379
  • [23] REGULATION OF GENE TRANSCRIPTION BY JNK AND P38 MAPK SIGNALING PATHWAYS IN SCHISTOSOMA MANSONI
    Gava, Sandra Grossi
    Tavares, Naiara
    Salim, Anna
    Araujo, Flavio
    Oliveira, Guilherme
    Mourao, Marina
    AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2017, 97 (05): : 182 - 182
  • [24] C-phycocyanin protects against ischemia-reperfusion injury of heart through involvement of p38 MAPK and ERK signaling
    Khan, M
    Varadharaj, S
    Ganesan, LP
    Shobha, JC
    Naidu, MU
    Parinandi, NL
    Tridandapani, S
    Kutala, VK
    Kuppusamy, P
    AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2006, 290 (05): : H2136 - H2145
  • [25] RG108 attenuates acute kidney injury by inhibiting P38 MAPK/FOS and JNK/JUN pathways
    Kong, Fan-xu
    Liu, Hui
    Xu, Tao
    Li, Shuang-jian
    Li, Wei
    Lu, Hao
    Ma, Nan-nan
    Wang, Yun-long
    Shi, Ji-hong
    Yang, Ya-ru
    Wang, Feng-ling
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2024, 142
  • [26] Minocycline protects melanocytes against H2O2-induced cell death via JNK and p38 MAPK pathways
    Song, Xiuzu
    Xu, Aie
    Pan, Wei
    Wallin, Brittany
    Kivlin, Rebecca
    Lu, Shan
    Cao, Cong
    Bi, Zhigang
    Wan, Yinsheng
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2008, 22 (01) : 9 - 16
  • [27] Melatonin protects against heart ischemia-reperfusion injury by inhibiting mitochondrial permeability transition pore opening
    Petrosillo, Giuseppe
    Colantuono, Giuseppe
    Moro, Nicola
    Ruggiero, Francesca M.
    Tiravanti, Edy
    Di Venosa, Nicola
    Fiore, Tommaso
    Paradies, Giuseppe
    AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2009, 297 (04): : H1487 - H1493
  • [28] Lycopene protects against myocardial ischemia-reperfusion injury by inhibiting mitochondrial permeability transition pore opening
    Li, Xuying
    Jia, Pengyu
    Huang, Zijun
    Liu, Shuang
    Miao, Jiaxin
    Guo, Yuxuan
    Wu, Nan
    Jia, Dalin
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2019, 13 : 2331 - 2342
  • [29] Curcumin Protects Against Regional Myocardial Ischemia/Reperfusion Injury Through Activation of RISK/GSK-3β and Inhibition of p38 MAPK and JNK
    Jeong, Cheol-Won
    Yoo, Kyung Yeon
    Lee, Seong Heon
    Jeong, Hye Jin
    Lee, Cha Sup
    Kim, Seok Jai
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, 2012, 17 (04) : 387 - 394
  • [30] Trans-cinnamaldehyde attenuates renal ischemia/reperfusion injury through suppressing inflammation via JNK/p38 MAPK signaling pathway
    Chen, Lichen
    Yuan, Jixiang
    Li, Hang
    Ding, Yi
    Yang, Xuejia
    Yuan, Ziwei
    Hu, Zujian
    Gao, Yuanyuan
    Wang, Xilong
    Lu, Hong
    Cai, Yong
    Bai, Yongheng
    Pan, Xiaodong
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2023, 118